D3.144 - Did allergic status change the quality of life in controlled severe asthma patients with triple therapy?

Severe allergic asthma patients (SAAP) typically experience more problems than those with non-allergic asthma (SNAAP).  This study aims to demonstrate the difference in quality of life among patients with controlled severe asthma receiving triple therapy, depending on their allergy. 

This single tertiary centre study is a prospective, cross-sectional and real-life study.  Controlled severe asthma patients (Asthma Control Test ≥ 20) with triple therapy (ICS/LABA/LAMA) were asked by the Severe Asthma Questionnaire (SAQ). Depending on their allergic status (prick test and allergic symptoms), patients' results were compared.

Twenty-two SAAPs (mean age: 48.5±13.5) and 24 SNAAPs (mean age: 53.5±10.2) completed this study. The duration of asthma, body mass index, and smoking history did not differ between the two groups (p > 0.05).  The education level of SNAAP was lower than that of SAAP (p=0.002). Spirometric parameters were not different between the two groups, with FEV1 82.5±18.5% in SNAAP and 76.2±20.3% in SAAP (p>0.05). Their SAQ levels (Table 1) did not differ between the two groups (p>0.05).  

The allergic status did not change the quality of life in controlled severe asthma patients.